Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gary L. Pattee, Angela Genge, Philippe Couratier, Christian Lunetta, Gen Sobue, Masashi Aoki, Hiide Yoshino, Carlayne E. Jackson, James Wymer, Alejandro Salah & Sally Nelson. (2023) Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics 0:0, pages 1-8.
Read now
Read now
Joseph M. Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda, Shawn Liu, Jeffrey Zhang & Wendy Agnese. (2019) Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:5-6, pages 421-431.
Read now
Read now
Articles from other publishers (12)
Elisa Duranti & Chiara Villa. (2023) Muscle Involvement in Amyotrophic Lateral Sclerosis: Understanding the Pathogenesis and Advancing Therapeutics. Biomolecules 13:11, pages 1582.
Crossref
Crossref
Luca Muzio, Alma Ghirelli, Federica Agosta & Gianvito Martino. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
523
537
.
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang & Stephen Apple. (2022) Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLOS ONE 17:6, pages e0258614.
Crossref
Crossref
Tianzhong Li, Xueyan Hou, Yu Qi, Xiaohan Duan, Pengcheng Yan, Haoru Zhu, Zhongjian Xie & Han Zhang. (2021) Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. Nano Research 15:4, pages 3299-3322.
Crossref
Crossref
KatherineL Marshall & MohamedH Farah. (2021) Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders. Neural Regeneration Research 16:10, pages 1901.
Crossref
Crossref
Hisaka Kurita, Saori Yabe, Tomoyuki Ueda, Masatoshi Inden, Akiyoshi Kakita & Isao Hozumi. (2020) MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 21:12, pages 4482.
Crossref
Crossref
William R. Swindell, Colin P. S. Kruse, Edward O. List, Darlene E. Berryman & John J. Kopchick. (2019) ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. Journal of Translational Medicine 17:1.
Crossref
Crossref
Nana Tian, Liyun Zhang, Zunbo Li, Jianjun Liu, Guohua Lei & Yanyan Ma. (2019) Big data of clinical manifestations combined with neuroelectrophysiologic features in the early diagnosis of motor neuron disease. Journal of Ambient Intelligence and Humanized Computing 10:10, pages 3879-3888.
Crossref
Crossref
Rocio Garcia-Santibanez, Matthew Burford & Robert C. Bucelli. (2018) Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update. Current Neurology and Neuroscience Reports 18:12.
Crossref
Crossref
Amit U Joshi, Nay L Saw, Hannes Vogel, Anna D Cunnigham, Mehrdad Shamloo & Daria Mochly‐Rosen. (2018) Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Molecular Medicine 10:3.
Crossref
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref
Crossref
Said R Beydoun & Jeffrey Rosenfeld. (2018) Edaravone in Amyotrophic Lateral Sclerosis’Lessons from the Clinical Development Program and the Importance of a Strategic Clinical Trial Design. US Neurology 14:1, pages 47.
Crossref
Crossref